Joseph McGowan, MD

Medical Director, Center for AIDS Research and Trteatment, North Shore University Hospital

Professor of Medicine, Hofstra Northwell School of Medicine

Phone: (516) 562-4280
Email: jmcgowan@northwell.edu

About the Investigator

Joseph P. McGowan, MD has provided HIV Primary Care to persons infected with HIV/AIDS for nearly 30 years. He is Board Certified in Infectious Diseases and Credentialed as an HIV Specialist by the American Academy of HIV Medicine (AAHIVM). He received a BA degree from Columbia University (summa cum laude), MD from the Mount Sinai School of Medicine and has completed a fellowship in Infectious Diseases and an NIH Fellowship in Immunology at the Albert Einstein College of Medicine.

Dr. McGowan is Professor of Medicine at the Hofstra Northwell School of Medicine and on faculty at the Albert Einstein School of Medicine. He is the chair of the New York/New Jersey Chapter Board of the American Academy of HIV Medicine. He has been the Director of HIV Ambulatory Care at the Bronx Lebanon Hospital Center and currently is Medical Director of the Center for AIDS Research & Treatment at the North Shore University Hospital on Long Island, NY. He has been involved in numerous HIV clinical trials for over 20 years.

Dr. McGowan has published over 60 original articles and abstracts dealing with HIV and AIDS. He is currently the Principal Investigator on over a dozen grant funded programs to provide HIV Primary Care and Prevention from the CDC, HRSA and New York State Department of Health. He serves as the Medical/Clinical Director of the AIDS Education and Training Regional Center at SUNY Stony Brook.

Research Focus

HIV and AIDS with a particular focus on HIV drug resistance, Management of HIV in Pregnancy, Anal Cancer Screening in HIV and the role of alteration in the microbiota in HIV immune reconstitution.

Education

Mount Sinai School of Medicine
Degree: MD
1987

Columbia University
Degree: BA
1983

Honors and Awards

2015 World AIDS Day Award for Outstanding Provider, United Way of Long Island
2013 Best Doctors in America
2011 Elected Fellow in the Infectious Diseases Society of America
2010 America’s Top Doctors, Castle Connolly
2008 Attending Physician of the Year Award, North Shore University Hospital
2004 Elected Fellow in the American College of Physicians
1990 Leo M. Davidoff Society Award for Outstanding Achievement in the Training of Medical Students, Albert Einstein College of Medicine, Yeshiva University
1983 Phi Beta Kappa
1983 Summa Cum Laude

Publications
  1. McGowan JP, Shah SS, Small CB, Klein RS, Schnipper SM, Chang CJ, Rosenstreich DL:  “Relationship of serum immunoglobulin and IgG subclass levels to race, ethnicity, and behavioral characteristics in HIV infection.” Med Sci Monit 12:1:CR11-16, 2005.
  2. Shah SS, McGowan JP, Klein RS, Converse PJ, Blum S, Gourevitch MN: “Agreement Between Mantoux Skin Testing and QuantiFERON® -TB Assay Using Dual Mycobacterial Antigens in Current and Former Injection Drug Users.”  Med Sci Monit 12:4:MT11-16, 2006.
  3. Alagappan K, McGowan J, DeClaro D, Ng D, Silverman RA.  “Tetanus Antibody Protection among HIV infected US born patients and Immigrants.”  International Journal of Emergency Medicine 1:123-126, 2008.
  4. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams (McGowan JP).  “Maraviroc for previously treated patients with R5 HIV-1 infection.” N Engl J Med. 2008 Oct 2;359(14):1429-41.
  5. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams (McGowan JP).  “Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.”  N Engl J Med. 2008 Oct 2;359(14):1442-55.
  6. Chubineh S and McGowan J.  “Nausea and Vomiting in HIV: A Symptom Review.” Int J STD AIDS. 2008 Nov;19(11):723-8.
  7. Cervia LD, McGowan JP. and Weseley AJ.  “Clinical and Demographic Variables Related to Pain in HIV-infected Individuals Treated with Effective, Combination Antiretroviral Therapy (cART).” Pain Medicine. 2010 Volume 11 Issue 4, Pages 498 – 503.
  8. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team.  “Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.” Lancet. 2012 Jun 30;379(9835):2439-48. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.
  9. Nirupama Chandel, Hersh Goel, Mohammad Husain, Divya Salhan, Ashwani Malhotra, Joseph McGowan, and Pravin C. Singhal. “VDR hypermethylation and HIV-induced T cell loss.”  J Leukoc Biol. 2013 Apr;93(4):623-31.
  10. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team. “Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.” Lancet. 2012 Jun 30;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0.
  11. Griffin DO, Dharsee A, Rico JC, McGowan J: “The Increasing Frequency of Deaths Due to Malignancy in HIV+ Patients is Associated with Poor Viral Suppression, Low CD4 Counts, Decreased Vitamin D Levels and Integrase Inhibitor Therapy.”  Journal of Health Science 2014 2 (2014) 240-247. DOI: 10.17265/2328-7136/2014.05.005.
  12. Chandel N, Ayosolla K, Lan X, Rai P, Mikulak J, Husain M, Malhotra A, McGowan J, and Singhal P. “Renin Modulates HIV Replication in T cells.” Journal of Leukocyte Biology 2014 Jun 26. pii: JLB.2A0414-192R. PMID: 24970860.
  13. Griffin DO, Metzger M, Poeth K, Deng K, Dharsee A, Rico JC, McGowan J. “Malignancies, Particularly B-cell Lymphomas, are a Frequent Cause of Mortality in HIV-1 Patients Despite HAART.” Open Forum Infectious Diseases, 2:147, 2015.
  14. Rico JC, Schwartz RM, McGowan J, Griffin DO (2015) “The Presence of a Malignant Comorbidity is a Significant Predictor of Increased 30-Day Hospital Readmission Rates in HIV-1 Infected Individuals.” J AIDS Clin Res 6: 532, 12/26/2015. doi:10.4172/2155-6113.1000532.
  15. Griffin DO, Metzger MJ, Bharti S, Dharsee A, Rico JC, McGowan J. (2016) “Coinfection with Hepatitis C Virus Increases Mortality in HIV-1 Infected Patients through Increased Liver-Related Deaths Rather Than By Increasing Malignancy Related Deaths.” J AIDS Clin Res 7:558. doi:10.4172/2155-6113.1000558.

View more at PubMed